Moderna to Present at Upcoming Conferences in December 2024
Rhea-AI Summary
Moderna (MRNA) has announced its upcoming participation in two major investor conferences in December 2024. The company will present at the 7th Annual Evercore ISI HealthCONx Conference on December 4th at 1:20pm ET, followed by the Piper Sandler 36th Annual Healthcare Conference on December 5th at 10:30am ET.
Live webcasts of both presentations will be accessible through the Investors section of Moderna's website under 'Events and Presentations.' Recordings will remain available for at least 30 days after each presentation.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, MRNA gained 6.20%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:
7th Annual Evercore ISI HealthCONx Conference, on Wednesday, December 4th at 1:20pm ET
Piper Sandler 36th Annual Healthcare Conference, on Thursday, December 5th at 10:30am ET
A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on accesswire.com